Literature DB >> 27416333

The prognostic impact of bone marrow fibrosis in primary myelofibrosis.

Paola Guglielmelli1,2, Alessandro M Vannucchi3,4.   

Abstract

Entities:  

Mesh:

Year:  2016        PMID: 27416333     DOI: 10.1002/ajh.24482

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  4 in total

1.  Bone marrow fibrosis grade is an independent risk factor for overall survival in patients with primary myelofibrosis.

Authors:  B Li; P Zhang; G Feng; Z Xu; T Qin; Y Zhang; Z Sha; D Dong; H Zhang; L Fang; L Pan; N Hu; S Qu; W Cai; G Huang; Z Xiao
Journal:  Blood Cancer J       Date:  2016-12-09       Impact factor: 11.037

Review 2.  Myelofibrosis Treatment Algorithm 2018.

Authors:  Ayalew Tefferi; Paola Guglielmelli; Animesh Pardanani; Alessandro M Vannucchi
Journal:  Blood Cancer J       Date:  2018-07-31       Impact factor: 11.037

3.  Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis.

Authors:  Hans Michael Kvasnicka; Jürgen Thiele; Carlos E Bueso-Ramos; William Sun; Jorge Cortes; Hagop M Kantarjian; Srdan Verstovsek
Journal:  J Hematol Oncol       Date:  2018-03-15       Impact factor: 17.388

4.  CCL2 rs1024611Gene Polymorphism in Philadelphia-Negative Myeloproliferative Neoplasms.

Authors:  Hossam Hodeib; Dina Abd El Hai; Mohamed A Tawfik; Alzahraa A Allam; Amal Selim; Abdallah Ahmed Elsawy; Amira Youssef
Journal:  Genes (Basel)       Date:  2022-03-10       Impact factor: 4.096

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.